Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05062486 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of RQC for AMD
A Phase 2 study of Age-related Macular Degeneration, sponsored by Paul A Knepper, MD PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT05062486 is a Phase 2 study of Age-related Macular Degeneration that has completed, run by Paul A Knepper, MD PhD. The registered enrollment target is 55 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05062486, a Phase 2 study of Age-related Macular Degeneration, has completed, sponsored by Paul A Knepper, MD PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).
Conditions Studied
Interventions
- DRUG Curcumin
- DRUG Resveratrol, Quercetin, Curcumin (RQC)
Study Locations (1)
Illinois
- Zaparackas M.D. & Knepper M.D. Ph.D., Ltd - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05062486
The ClinicalTrials.gov registry entry for NCT05062486 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The listed sponsor is Paul A Knepper, MD PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Curcumin is the first listed.
NCT05062486 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05062486 about?
NCT05062486 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of RQC for AMD". To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).
What is the current status of trial NCT05062486?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2021-10-04. Estimated completion is 2024-11-07.
What conditions does trial NCT05062486 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT05062486?
The interventions under investigation include: Curcumin (DRUG), Resveratrol, Quercetin, Curcumin (RQC) (DRUG).
Who is sponsoring clinical trial NCT05062486?
This trial is sponsored by Paul A Knepper, MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05062486 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 2
-
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
COMPLETED · Phase 2
-
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
COMPLETED · Phase 2
-
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
COMPLETED · Phase 2
-
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.